Clinical Trials Logo
  1. Home
  2. Atypical Parkinsonism
  3. NCT06122662

AMX0035 and Progressive Supranuclear Palsy — ORION  

Neurodegenerative Diseases Clinical Trial

Official title:
A Phase 3 Study of Safety and Efficacy of AMX0035 in Progressive Supranuclear Palsy (ORION)

Clinical Trial Summary

ORION Trial is a trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of a randomized double blind placebo controlled phase, followed by an optional open-label extension phase.

Clinical Trial Description

AMX0035 is a combination therapy designed to reduce neuronal death through blockade of key cellular death pathways originating in the endoplasmic reticulum (ER) and mitochondria. This clinical trial is designed to demonstrate that AMX0035 is safe and tolerable, and to assess its effect on disease progression as measured by the Progressive Supranuclear Palsy (PSP) Rating Scale (PSPRS) over a 52-week double-blind phase. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06122662
Study type Interventional
Source Amylyx Pharmaceuticals Inc.
Contact The Harte Group
Phone +44 (808) 1642604
Email clinicaltrials@amylyx.com
Status Recruiting
Phase Phase 3
Start date December 21, 2023
Completion date May 31, 2027
View Details
See also
  Status Clinical Trial Phase
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Completed NCT05788133 - The Role of Humanoid Robot in Neuropsychological Assessment and Cognitive Training. N/A
Completed NCT05080777 - Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems N/A
Completed NCT03295786 - Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease Phase 1/Phase 2
Recruiting NCT04265482 - Community-based Cohort of Functional Decline in Subjective Cognitive Complaint Elderly
Not yet recruiting NCT02222779 - Quantification of Transition Metals N/A
Recruiting NCT01291550 - Electronic Nose for Diagnosis of Neurodegenerative Diseases Via Breath Samples N/A
Completed NCT01450891 - Health Technology Assessment of Diagnostic Approaches in Alzheimer's Disease N/A
Completed NCT01953523 - Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions N/A
Recruiting NCT06148233 - CSF1R PET Probe [18F]CSF-23 in Alzheimer's Disease Brain Imaging N/A
Completed NCT03538522 - A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831 Phase 2
Completed NCT06251830 - Increasing Diagnosis Rates While Reducing Examination Time: Can MR Fingerprinting Deliver on Its Promise?
Recruiting NCT04472130 - Neurodegenerative Diseases Registry
Completed NCT03353207 - Striatal Dopamine Transmission in Individuals With Isolated Rapid Eye Movement Sleep With Atonia: a Search for Precursor Biomarker for Neurodegeneration
Completed NCT05095870 - Evaluation of the Peripheral Nerve Ultrasound as a Diagnostic Tool in CANVAS Neuropathies
Recruiting NCT05784090 - Correlation Between Melatonin Levels in Different Biological Fluids
Completed NCT02108769 - Yogic Breathing Changes Salivary Components N/A
Recruiting NCT05508789 - A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5) Phase 3
Recruiting NCT05235802 - Long-term Follow-up in Severe Traumatic Brain Injury
Recruiting NCT04820881 - Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain Injury